A systematic approach to assessing the clinical significance of genetic variants

Molecular genetic testing informs diagnosis, prognosis, and risk assessment for patients and their family members. Recent advances in low‐cost, high‐throughput DNA sequencing and computing technologies have enabled the rapid expansion of genetic test content, resulting in dramatically increased numb...

Full description

Saved in:
Bibliographic Details
Published in:Clinical genetics Vol. 84; no. 5; pp. 453 - 463
Main Authors: Duzkale, H, Shen, J, McLaughlin, H, Alfares, A, Kelly, MA, Pugh, TJ, Funke, BH, Rehm, HL, Lebo, MS
Format: Journal Article
Language:English
Published: Oxford, UK Blackwell Publishing Ltd 01-11-2013
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Molecular genetic testing informs diagnosis, prognosis, and risk assessment for patients and their family members. Recent advances in low‐cost, high‐throughput DNA sequencing and computing technologies have enabled the rapid expansion of genetic test content, resulting in dramatically increased numbers of DNA variants identified per test. To address this challenge, our laboratory has developed a systematic approach to thorough and efficient assessments of variants for pathogenicity determination. We first search for existing data in publications and databases including internal, collaborative and public resources. We then perform full evidence‐based assessments through statistical analyses of observations in the general population and disease cohorts, evaluation of experimental data from in vivo or in vitro studies, and computational predictions of potential impacts of each variant. Finally, we weigh all evidence to reach an overall conclusion on the potential for each variant to be disease causing. In this report, we highlight the principles of variant assessment, address the caveats and pitfalls, and provide examples to illustrate the process. By sharing our experience and providing a framework for variant assessment, including access to a freely available customizable tool, we hope to help move towards standardized and consistent approaches to variant assessment.
Bibliography:Appendix S1. Variant Assessment ToolAppendix S2. Variant Assessment SOPAppendix S3. Variant Assessment Static Data
National Institutes of Health - No. HG006834; No. HG006500
ark:/67375/WNG-41S0RTG8-R
istex:E40D9BA349C55483885FA5E8A630ED3DE5DDF980
ArticleID:CGE12257
These authors contributed equally to this work.
H. D., J. S., H. M., M. A. K., T. J. P., B. H. F., H. L. R. and M. S. L. are employed by fee‐for‐service laboratories performing clinical sequencing services. Several individuals serve on advisory boards or in other capacities for companies providing sequencing or other genetic services (H. L. R.—BioBase, Clinical Future, Complete Genomics, GenomeQuest, Illumina, Ingenuity, Knome, Omicia; B. F.—InVitae; J. S.—LabCorp).
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0009-9163
1399-0004
DOI:10.1111/cge.12257